ConductScience.org, home

Paper28612401

Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.

Abdel Raheem A and 9 others. BJU Int, 2017. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. Papers, record 28612401. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28612401

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol.
PubMed
Journal
BJU Int
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
5.31
iCite
Revised in PubMed
2018-03-05
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Abdel Raheem AAmrhttps://orcid.org/0000-0002-5505-9291
2Capece MMarco
3Kalejaiye OOdunayohttps://orcid.org/0000-0003-4065-0801
4Abdel-Raheem TTarek
5Falcone MMarco
6Johnson MMark
7Ralph OGOliver G
8Garaffa GGiulio
9Christopher ANAndrew N
10Ralph DJDavid J

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Microbial CollagenaseMajor topic
Penile IndurationMajor topic
Adult
Aged
Humans
Injections, Intralesional
Male
Middle Aged
Penis
Prospective Studies
Treatment Outcome

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in29144915Re: Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease Using a New Modified Shortened Protocol.https://conductscience.org/library/papers/29144915

Source PubMed

Download CSV of comments and corrections

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
41971130Current status of non-surgical treatments for Peyronie's disease.Transl Androl Urol2026https://conductscience.org/library/papers/41971130PubMed
41821908A novel approach to Peyronie's disease: Intralesional injection of lyophilized platelet-derived growth factors.Cent European J Urol2026https://conductscience.org/library/papers/41821908PubMed
41777620Contemporary Management Strategies for Peyronie's Disease: A Comprehensive Review.Res Rep Urol2026https://conductscience.org/library/papers/41777620PubMed
41407896Targeting the acute phase of Peyronie's disease: preliminary experience with Perovial®, a novel hyaluronic acid formulation.Int J Impot Res2025https://conductscience.org/library/papers/41407896PubMed
40358122Editorial comment on "Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil".Asian J Androl2025https://conductscience.org/library/papers/40358122PubMed
40314553Outcomes and management of Peyronie's disease with combined treatment of collagenase clostridium histolyticum, vacuum erection device, and tadalafil.Asian J Androl2025https://conductscience.org/library/papers/40314553PubMed
39450208A review of Peyronie's disease insurance coverage.Sex Med2024https://conductscience.org/library/papers/39450208PubMed
37550385Safety and feasibility of percutaneous needle tunneling with platelet-rich plasma injections for Peyronie's disease in the outpatient setting: a pilot study.Int J Impot Res2024https://conductscience.org/library/papers/37550385PubMed
36756281Peyronie's Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities.Res Rep Urol2023https://conductscience.org/library/papers/36756281PubMed
36569498Improvement in the ability to have sex in patients with Peyronie's disease treated with Collagenase Clostridium histolyticum.BJUI Compass2023https://conductscience.org/library/papers/36569498PubMed
36303674Global Perspective on the Management of Peyronie's Disease.Front Reprod Health2022https://conductscience.org/library/papers/36303674PubMed
36068002
Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.
Investig Clin Urol2022https://conductscience.org/library/papers/36068002PubMed
34552787Peyronie's disease - outcomes of collagenase clostridium histolyticum injection: A systematic review.Arab J Urol2021https://conductscience.org/library/papers/34552787PubMed
33471204The Management of Penile Fracture: a Review of the Literature with Special Consideration for Patients Undergoing Collagenase Clostridium Histolyticum Injection Therapy.Curr Urol Rep2021https://conductscience.org/library/papers/33471204PubMed
33420664Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Curr Urol Rep2021https://conductscience.org/library/papers/33420664PubMed
33420247Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie's disease in a multicenter clinical study.Sci Rep2021https://conductscience.org/library/papers/33420247PubMed
32518629Recent advances in managing Peyronie's disease.F1000Res2020https://conductscience.org/library/papers/32518629PubMed
32366987Treatment of peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study.Int J Impot Res2021https://conductscience.org/library/papers/32366987PubMed
32317742About the drawback of collagenase.Int J Impot Res2021https://conductscience.org/library/papers/32317742PubMed
32257868Minimally invasive therapies for Peyronie's disease: the current state of the art.Transl Androl Urol2020https://conductscience.org/library/papers/32257868PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28612401

GET https://conductscience.org/api/papers/v1/28612401/cited_by?page=2